Navigation Links
Micromet Announces Changes in Management Team
Date:12/14/2007

BETHESDA, Md., Dec. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the resignation of Christopher Schnittker as Senior Vice President and Chief Financial Officer. Donald A. Zelm, Executive Director Finance, will assume the responsibilities as principal financial officer of the Company and as its interim chief financial officer. He will oversee the Company's financial operations until a new chief financial officer is hired. The Company has initiated a search for a new CFO.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody in Micromet's product pipeline developed utilizing the BiTE(R) antibody technology platform, is being evaluated in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of Astra Zeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 On September 25 to 26, ... on medical design and manufacturing - MEDTEC China  - ... Expo Exhibition & Convention Center, bringing together close to ... to showcase their latest medical-grade raw materials, parts and ... week remaining for free visitor pre-registration to be completed. ...
(Date:9/16/2014)... Sept. 16, 2014 The Lupus Foundation of ... LLY ) today released results from UNVEIL: understanding the ... on the lupus journey and the challenges not only ... caregivers. The UNVEIL study, which involved over 1,000 people ... lupus has on all aspects of life including family, ...
(Date:9/16/2014)... HOUSTON , Sept. 16, 2014  DNAtrix, ... that the first patient was treated with the ... plus gamma interferon in a randomized, multicenter, open-label ... "DNAtrix, in collaboration with leading neurosurgeons ... announce the initiation of our randomized Phase Ib ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... Scientists from the Barbara Ann Karmanos Cancer Institute in ... therapeutic agents used to promote bone health and inhibit resorption, ... with early stage breast cancer who take them for their ... American Society of Clinical Oncology Annual Meeting. , ...
... Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in ... today provided further details about worldwide patent protection for its breast ... , , ... as its independent auditor.  Abviva is working hard to regain compliance ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4Abviva Engages W.T. Uniack & Co. As Independent Auditor 2
(Date:9/16/2014)... 2014 An experienced review website, ... and announced that Bluehost and HostGator.com are among ... want to purchase high quality web hosting (including ... visit their websites now. , BlueHost ( ... established itself as a reliable and long-standing force ...
(Date:9/16/2014)... Pulmonary Hypertension Association Travels to San Diego for ... Patients and Families to Help Fight Rare Lung Disease , ... pulmonary hypertension association that works to find ways to prevent ... lungs that affects the functioning of the heart and can ... only 2.8 years. , What:, PHA On The ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 ... hosting suppliers from the USA and announces ... ) are the best Windows web hosting ... on offering worldwide clients high quality WordPress ... low rates. , HostMonster provides outstanding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2
... Modifying gene called Foxp3 may develop cells capable of ... -- New understanding about how to control autoimmune responses ... arthritis (RA), British researchers say. , RA -- a ... body,s immune system attacks itself. A molecule called Foxp3 ...
... financial, operational, and clinical visibility to ... ... Fla., Nov. 13 Sentry Data Systems,today announced HealthBIT, a ... and clinical,visibility to hospitals by qualifying, aggregating, and comparing their,data ...
... Found with Free, Online Resources -, White ... paying out-of-pocket to fill prescriptions, and with those ... "Safe,Strategies for Drug Savings" today on its site ... in the U.S., Canada, and other,countries as well, ...
... Access to the Power of the Xevo TQ System,s Quantitative ... ... MILFORD, Mass., Nov. 13 Focused on the,process of helping firms ... ) will showcase innovative,UltraPerformance LC(R) (UPLC) and mass spectrometry (MS) solutions ...
... suite enables payors to compete like ... evolving healthcare marketplace, BURLINGTON, Mass., Nov. 13 ... platform for healthcare payors,today announced that it will ... 2008 Gartner Healthcare Summit. The,conference will be held ...
... Patients with advanced non-small cell lung cancer whose ... rate of tumor shrinkage and a longer interval ... standard second-line erlotinib therapy, according to a study ... Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and ...
Cached Medicine News:Health News:New Therapy Could Transform Arthritis Treatment 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 3Health News:HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit 2
... system has been designed to enhance fixation ... cluster hole configurations. The objective of the ... three primary modes: Tilt, migration and rotation. ... in initial and long-term fixation. The porous ...
Optimal solution for normal acetabulum and younger patients....
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
Medicine Products: